Atypisches Opioid: Was der Fachbegriff bei Mitragynin bezeichnet - Kratoein

Atypical Opioid: What the Technical Term Means for Mitragynine

Anyone who looks closely at the constituents of the leaves of Mitragyna speciosa will run into the label "atypical opioid" again and again in the scientific literature. This article explains what the term denotes, what the classification of mitragynine actually rests on, and what research has made of it since 2016. One part of that record is well documented, another part is disputed among specialists, and a third part, which is usually missing from popular accounts, speaks in favor of the substance. All three are set out side by side here.

Where the term comes from

The expression goes back to a paper by Kruegel and colleagues that appeared in 2016 in the Journal of the American Chemical Society. Its title contains the phrase "atypical molecular framework". What is meant by that, in the first instance, is something purely chemical (Kruegel et al., JACS 2016).

Morphine and most of the substances related to it belong to the group of morphinans and come from the opium poppy (Papaver somniferum). Mitragynine, by contrast, is an indole alkaloid of the corynanthe type. An alkaloid is a nitrogen-containing plant constituent; "indole" refers to a particular ring building block inside the molecule. The plant itself belongs to the madder family, the same botanical family as the coffee shrub. Between the two classes of compound there is no chemical kinship at all.

That molecules from both groups nevertheless dock onto the same target molecule, the µ-opioid receptor, is a case of convergence: two molecular shapes that arose independently of one another and happen to fit the same binding pocket. This is the uncontested part of the term.

One receptor, more than one exit

A receptor is not a switch with exactly one outcome. When a molecule binds to the µ-opioid receptor, the cell can respond in at least two ways. One pathway runs through so-called G proteins, signaling molecules inside the cell. The other consists of a protein named beta-arrestin-2 being recruited to the receptor; it dampens the signal and pulls the receptor from the cell surface into the interior of the cell. If a molecule drives one pathway more strongly than the other, the technical vocabulary speaks of "functional selectivity" or "biased agonism". "Agonist" here simply means a substance that activates a receptor.

A far-reaching hope was attached to this distinction. Experiments in genetically modified mice from the late 1990s suggested that the respiratory depression measured in animal studies arises rather via the beta-arrestin pathway, while the elevation of the pain threshold measured there arises rather via the G protein pathway. From this came the idea that a molecule which drives only one of the two pathways might change one measured variable without triggering the other.

What the cell experiments on mitragynine showed

The 2016 finding fitted neatly into that picture. In cell cultures, that is, in cultivated cell lines that produce the receptor artificially, mitragynine activated the G protein pathway but barely recruited beta-arrestin-2. The same was described for 7-hydroxymitragynine and for mitragynine pseudoindoxyl, two closely related molecules. What was measured was therefore a signaling pattern in a cell line. Since then, mitragynine has turned up regularly in review articles as a textbook example of a biased ligand.

Partial agonist rather than full agonist

A second observation from the same paper concerns not the direction but the magnitude of the response. Morphine and fentanyl count as full agonists: they drive the receptor to the maximum of what the test system is able to display. Mitragynine was described as a partial agonist, meaning that even when, on paper, every available receptor is occupied, the measured response stays below that maximum.

A simulation of the receptor's movements in a computational model arrived in 2026 at a picture that matches this: mitragynine holds the receptor in an intermediate position instead of converting it fully into the active conformation (Scientific Reports 2026).

The built-in ceiling: the 2022 finding

The most remarkable finding on mitragynine from today's vantage point dates from 2022, and it concerns precisely the variable that is decisive with opioids: breathing. First, the relationship on which it rests. In 2019 a paper in ACS Central Science showed that mitragynine is converted into 7-hydroxymitragynine in liver preparations from mouse and human, above all by enzymes of the cytochrome P450 3A family (Kruegel et al. 2019). This metabolite is considerably more potent at the µ-opioid receptor than the parent compound; in the mouse experiment the authors attributed to it the essential share of the elevation of the pain threshold measured there. Mitragynine therefore behaves in part like a prodrug, a substance that is converted into the more active form only inside the body.

In 2022 a group around Hill examined in the British Journal of Pharmacology what this conversion step means for breathing. Measurements were taken in awake, freely moving mice by whole-body plethysmography, with administration through the gastrointestinal tract. The result: the respiratory depressant effect of mitragynine showed a ceiling effect. Above 10 mg per kilogram of body weight, higher doses no longer produced any stronger depression. 7-hydroxymitragynine itself behaved differently; there the effect continued to increase with the dose. And when the researchers blocked the converting enzyme CYP3A, the respiratory depressant effect of mitragynine came out smaller, while that of 7-hydroxymitragynine remained unchanged (Hill et al., British Journal of Pharmacology 2022).

The explanation the authors derive from this is strikingly simple. Because the conversion into the more potent metabolite is limited, since the enzyme does not work any faster above a certain amount, more parent compound stops yielding more metabolite beyond a certain point. The ceiling is thus not a property of the receptor but a property of metabolism. The paper concludes that this "metabolic saturation" at high doses may underlie the more favorable safety profile the authors discuss for mitragynine as a possible drug candidate.

This recasts the prodrug property. For the question of which signaling profile one is actually measuring, it remains a methodological complication: whoever administers mitragynine in an animal experiment and then measures effects is in part measuring the metabolite as well. For the dose-response curve, however, that very same circumstance is precisely the reason for the observed ceiling. Both hold at the same time, and the second point has long been overlooked.

The finding comes from a mouse model using male animals. How much metabolite is formed in humans is a separate question. In an investigation in healthy volunteers, the peak concentration and the total exposure of 7-hydroxymitragynine came to roughly 9 and 20 percent respectively of the corresponding values for the parent compound, and pretreatment with the CYP3A inhibitor itraconazole markedly lowered the 7-OH values (Mongar et al. 2024). The conversion pathway is therefore documented in humans as well, and the metabolite remains a small fraction there.

Atypical also means: more than one receptor system

A further part of the classification has nothing to do with the opioid receptor at all. In behavioral experiments in rats, Hiranita and colleagues compared mitragynine and morphine in 2019. The opioid blocker naltrexone, at doses that abolished the morphine effects, did not abolish the mitragynine effects. From this the authors concluded, in their own words, that the pharmacology of mitragynine comprises a "substantial non-opioid mechanism" (Hiranita et al., Psychopharmacology 2019).

The picture looks similarly layered at other receptor families. In the test tube, mitragynine also binds to adrenergic receptors; an investigation from 2025 describes it at human alpha-2A receptors as a weak blocker and at alpha-1 receptors as a weak partial activator (ACS Chemical Neuroscience 2025), while in behavioral experiments in rats effects were described that fit an activator better.

For the term "atypical" this is the second load-bearing reason: it is not only about a foreign molecular framework, but also about the fact that the observed effects cannot be traced back to a single receptor system.

How specialists have assessed the abuse potential

Alongside receptor research there is a second body of literature that rarely comes up: formal assessments of abuse potential. In the United States, the Controlled Substances Act provides a grid of eight factors for this purpose. In 2018 Henningfield, Fant and Wang published such an eight-factor analysis for mitragynine and 7-hydroxymitragynine in Psychopharmacology. Their conclusion: the abuse potential of mitragynine lies within the range of many other, uncontrolled substances, and there is no evidence of an imminent hazard to public health (Henningfield et al., Psychopharmacology 2018).

In 2021 an update followed in Frontiers in Pharmacology which evaluated more than 100 papers published since 2018: animal studies on abuse potential and withdrawal signs, receptor binding studies, pharmacokinetic investigations, clinical observations in long-term users, and surveys. In it the authors expressly recommend against scheduling under the Controlled Substances Act and advise instead a form of regulation that prevents contaminated, adulterated and inaccurately marketed products (Henningfield et al., Frontiers in Pharmacology 2021).

For the terminological question of this article, one passage from it is particularly pertinent. Because the mechanisms are diverse and in part not mediated through opioid receptors, describing mitragynine as an opioid "analogue" or as a "narcotic-like opioid" is, in the authors' view, not compatible with the overall evidence. The term "atypical", on this reading, is not a softener but an attempt to name precisely that lack of sharp definition.

Assessments were also carried out outside the United States. The Expert Committee on Drug Dependence of the World Health Organization dealt with Mitragyna speciosa, mitragynine and 7-hydroxymitragynine in a pre-review in October 2021 and concluded that the available data were insufficient for a full review with a view to international control; the substances should remain under surveillance (WHO, report of the Expert Committee on Drug Dependence, 44th meeting).

Part of a fair assessment is that the authors of the eight-factor analyses work for a consulting firm which, among other clients, advises an industry association, and that several of the pharmacological papers involve authors holding patents in the area of mitragynine analogues. All of them disclose this. It does not devalue the peer-reviewed findings, but it belongs to the complete picture.

The counter-argument: perhaps never bias, only weakness

So much for the findings that speak in favor of the substance. There is a counter-argument worth taking seriously, and it does not attack the breathing data but the narrative of bias. Three independent points are affected.

First, the underlying hypothesis. In 2020 a group around Kliewer published replication experiments in the British Journal of Pharmacology that were carried out in parallel in laboratories in three countries. The result: in mice lacking beta-arrestin-2, the respiratory depression triggered by morphine was no smaller than in normal animals (Kliewer et al. 2020). A paper in eLife reached the same conclusion independently in 2021 (eLife 2021).

Second, the interpretation of the measurement data. Also in 2020, a paper by Gillis and colleagues in Science Signaling showed that the data on the best-known "biased" opioids can also be explained without invoking bias at all: these molecules are, on that reading, simply weaker agonists (Gillis et al. 2020). If a weak agonist is measured in a very sensitive test system, a strong signal is still visible there, while in the less sensitive beta-arrestin assay nothing arrives any more. The pattern would look like bias but would in fact be a difference in efficacy. In 2021 a reply appeared in Biochemistry which states already in its title that low intrinsic efficacy alone cannot explain the observations (Biochemistry 2021).

Third, the practical test case. Oliceridine was approved in the United States in 2020 as the first opioid explicitly developed as G protein biased. Its mechanism of action remains disputed to this day; a review from 2025 carries the phrase "contested mechanism of action" in its title (Journal of Opioid Management 2025).

What is remarkable is how little this counter-argument shakes the ceiling finding of 2022. It concerns the question of why a molecule shows a particular signaling pattern. The ceiling effect on breathing does not depend on that: it rests on the speed of an enzyme, not on the bias of a receptor.

What distorts the measurement itself

The dispute about bias is so persistent partly because the contested number depends on the experimental setup. Three adjusting screws are well documented.

Receptor density. Test cell lines produce far more receptors than natural tissue carries. This creates a receptor reserve: even weak activation is enough for a full signal, and differences in efficacy disappear inside that amplification.
Choice of assay. G protein and beta-arrestin measurements differ in sensitivity. A comparison between the two therefore compares not only molecules but also measurement techniques.
Choice of reference molecule. Bias is expressed relative to a reference compound, frequently the peptide DAMGO. With a different reference point, the calculated value shifts.

Part of what has been reported as a property of the substance is therefore a property of the laboratory, and that applies equally to all the molecules involved.

What is documented and what remains open

A whole series of things is documented: a chemically independent molecular framework; partial rather than full agonism at the µ-opioid receptor; a substantial share of effects that, in the animal model, is not mediated through opioid receptors; a metabolically limited conversion into a more potent metabolite, in humans as well; and, following from that, a ceiling effect on the respiratory depressant effect in the mouse model. Two successive assessments of abuse potential concluded that scheduling under the Controlled Substances Act was not indicated, and in 2021 the World Health Organization saw no reason for a full review.

Three points remain open. A signaling pattern in a cell line is a measured variable, not a result in a living organism. The ceiling effect was measured in mice; whether and in what dose range something corresponding appears in humans has not been investigated. And the origin of a molecule says nothing in itself about its behavior, which is, after all, exactly the starting point of this whole story.

After all of this, "atypical" is a precise designation: the molecule is chemically foreign, it engages more than one receptor system, and in the animal model it does not follow the dose-response logic of classical opioids. Whoever reads the term as a seal of quality loads more onto it than it can carry. Whoever dismisses it as a euphemism overlooks what the literature has assembled since 2018.

Legal notice

This article is for informational purposes only and does not constitute legal advice. Its content is not intended to encourage consumption. Laws may change; the applicable regulations and information from official bodies are authoritative. Image source: https://www.kratoein.com/

Back to blog